|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 |
|
| |||||||||||||||||||||||||||||
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) |
1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Reporting Owner Name / Address | Relationships | |||
Director | 10% Owner | Officer | Other | |
First Eagle Investment Management, LLC 1345 AVENUE OF THE AMERICAS NEW YORK, NY 10105 |
X | |||
First Eagle Value in Biotechnology Master Fund, Ltd. 1345 AVENUE OF THE AMERICAS NEW YORK, NY 10105 |
X | |||
21 APRIL FUND LTD 1345 AVENUE OF THE AMERICAS NEW YORK, NY 10105 |
X | |||
21 APRIL FUND LP 1345 AVENUE OF THE AMERICAS NEW YORK, NY 10105 |
X | |||
DEF Associates LP 1345 AVENUE OF THE AMERICAS NEW YORK, NY 10105 |
X | |||
DEF Associates Ltd. 1345 AVENUE OF THE AMERICAS NEW YORK, NY 10105 |
X |
First Eagle Investment Management, LLC, By: /s/ Mark Goldstein, Senior Vice President | 08/29/2013 | |
**Signature of Reporting Person | Date |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) | The shares of Common Stock to which this relates are held directly by First Eagle Value in Biotechnology Master Fund, Ltd., a Cayman Islands exempted company ("FEVIB"), 21 April Fund, Ltd., a Cayman Islands exempted company ("April LTD"), 21 April Fund, L.P., a Delaware limited partnership ("April LP"), DEF Associates, LP, a Delaware limited partnership ("DEF LP"), DEF Associates, Ltd., a British Virgin Islands corporation ("DEF LTD" and together with FEVIB, April LTD, April LP and DEF LP, the "Funds"), and certain managed accounts (collectively, the "Accounts"). |
(2) | The shares of Common Stock reported herein are indirectly beneficially owned by First Eagle Investment Management, LLC, a Delaware limited liability company and an investment adviser registered under the Investment Advisers Act of 1940 ("FEIM"), by virtue of its service as investment manager to the Funds and Accounts, which are under FEIM's management and control. Each of the reporting persons disclaims beneficial ownership of the securities to which this Form 4 relates for the purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except as to such extent of the reporting person's pecuniary interest in the securities. |